The United States Food and Drug Administration (FDA) announced by Twitter that it is “expediting” the creation of a CBD regulatory framework.
“FDA is expediting its work to address the many questions about cannabidiol (CBD),” said Dr. Amy Abernathy in a tweet. Dr. Abernathy is the FDA’s acting chief information officer. “This is an important national issue with public health impact.”
She added that the CBD regulatory framework is also an important topic for hemp farmers. The US legalized hemp in December 2018. That opened questions about when the US would legalize cannabis in 2019. Despite indications that Trump may be amenable to legalizing cannabis in the US, it is looking less like it will happen this year.
However, CBD is still a hot commodity in the US, despite the lack of framework. Neiman Marcus sells CBD-based beauty products. Nationwide chain CVS Pharmacy sells topical CBD products. Ben & Jerry’s has developed a CBD-infused ice cream. Even Martha Stewart believes cannabis is a good thing, partnering with Canopy Growth to develop CBD products for pets.
The Politics of CBD as a Health Product – LPC
CBD remedies are becoming more accepted. However, due to the fact that it has been illegal for so long, there is little research or hard science to back up medical claims. Further, the FDA cannot rubber-stamp a new CBD regulatory framework because, ironically, the FDA has already approved a cannabis-based drug. Epidiolex is a CBD-derived medication for treating epilepsy.
So, CBD is officially a drug in the FDA’s eyes, which means much more research would be needed. It could be years before there is officially a CBD regulatory framework in the US. That hasn’t stopped producers. Cannabis beverages are already on the rise within a legal grey area. In Canada, cannabis edibles legalization officially happens on October 17, 2019, but products won’t be available for sale until at least December.